1300031-92-8Relevant articles and documents
Design, Synthesis, and Characterization of I-BET567, a Pan-Bromodomain and Extra Terminal (BET) Bromodomain Oral Candidate
Atkinson, Stephen J.,Bamborough, Paul,Bit, Rino A.,Chung, Chun-Wa,Craggs, Peter D.,Cutler, Leanne,Davis, Rob,Ferrie, Alan,Gong, Gangli,Gordon, Laurie J.,Gray, Matthew,Harrison, Lee A.,Hayhow, Thomas G.,Haynes, Andrea,Henley, Nick,Hirst, David J.,Holyer, Ian D.,Humphreys, Philip G.,Lindon, Matthew J.,Lovatt, Cerys,Lugo, David,McCleary, Scott,Molnar, Judit,Osmani, Qendresa,Patten, Chris,Preston, Alex,Prinjha, Rab K.,Rioja, Inmaculada,Seal, Jonathan T.,Smithers, Nicholas,Sun, Fenglai,Tang, Dalin,Taylor, Simon,Theodoulou, Natalie H.,Thomas, Clare,Tomkinson, Nicholas C. O.,Watson, Robert J.,Wellaway, Christopher R.,Zhu, Linrong
, (2022/01/27)
Through regulation of the epigenome, the bromodomain and extra terminal (BET) family of proteins represent important therapeutic targets for the treatment of human disease. Through mimicking the endogenous N-acetyl-lysine group and disrupting the protein-
Tetrahydroquinoline Derivatives And Their Pharmaceutical Use
-
Page/Page column 23, (2012/08/28)
Tetrahydroquinoline compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.
THETRAHYDROQUINOLINES DERIVATIVES AS BROMODOMAIN INHIBITORS
-
Page/Page column 104, (2011/06/11)
Tetrahydroquinoline compounds of formula (I) or a salt thereof, pharmaceutical compositions containing such compounds and their use in therapy, in particular in the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.